Atrabin 250mg Injection

Atrabin 250mg Injection is an antineoplastic drug from the class of alkylating agents, containing the active ingredient Dacarbazine. It is used for prevention and treatment of metastatic malignant melanoma and Hodgkin's disease. It is often combined with cisplatin to treat certain cancer types including Hodgkin's lymphoma, and with temozolomide for melanoma treatment. Use of this medicine may carry an increased risk of non-melanoma skin cancer.

This drug is contraindicated in pregnant women. Women of childbearing potential should use effective contraception during treatment and for at least 6 months after completion. It is not established whether Atrabin 250mg Injection is excreted in human milk; breastfeeding should be avoided during treatment. Use with caution in patients with pre-existing liver or kidney dysfunction.

Live vaccines should not be administered during Atrabin 250mg Injection treatment, as the drug may weaken immune function and increase risk of serious infection. Contact your doctor immediately for further guidance.

Atrabin 250mg Injection may cause pain along the vein. Notify your nurse immediately if pain occurs so the infusion site can be assessed. The infusion rate may be reduced or additional fluids administered to minimise discomfort.

Treatment initiation requires white blood cell counts above specified levels. Your doctor will monitor these values at regular intervals. Do not use if you are allergic to Dacarbazine. Blood tests will be performed before each administration to confirm adequate blood cell counts for treatment.

This medicine is usually administered once every three to four weeks. Inform your physician of all recent medications, including herbal medicines and supplements, prior to receiving Atrabin 250mg Injection.

Metastatic malignant melanoma Hodgkin’s disease

It is a type of alkylating agent, which works majorly through the process of alkylation. It enters the cancer cells after getting activated by the liver and inhibits DNA synthesis. This process disrupts the normal cell cycle and DNA function, leading to arrest in cancer cell growth and multiplication.

The medicine will be administered to you by a healthcare professional in a hospital setting. This injection will be given intravenously into a vein in your arm or hand. Do not self-administer this medicine. The specific dose and schedule of administration depend on the type and stage of cancer being treated. Atrabin 250mg Injection is usually given about 30 minutes before you receive your anti-cancer medicine (chemotherapy). During the infusion, you will be monitored for any side effects or reactions to the medication. It is important to get the dose at the scheduled time. If you missed the schedule, contact your doctor and reschedule the dose.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious: Sore throat or high temperature indicating infection Unusual bleeding or bruising Severe vomiting or diarrhoea Extreme tiredness Severe allergic reaction, characterized by swelling of hands, feet, ankles, face, lips, mouth or throat; rashes or giddiness. Headache, vision problems, fits, confusion, lethargy or numbness of face Severe liver problems Common: Low levels of RBC, WBC and platelets in blood. Loss of appetite Nausea, vomiting Hair loss Skin reactions

Atrabin 250mg Injection can cause harm to a developing fetus or nursing baby, so it is important to discuss contraception options and the need to avoid breastfeeding during treatment. This drug causes fatigue, so encourage the patient to take enough rest and self-care during treatment. Atrabin 250mg Injection increases the risk of bleeding and bruising, so it is important to be careful when using sharp objects or participating in activities that may result in injury.